cyrilzakka/clinical-trials huggingface dataset:
The Leukemia and Lymphoma Society (LLS) National Research Registry

The Leukemia and Lymphoma Society (LLS) has built a National Research Registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.

The LLS National Research Registry is a real-world experiences and outcomes research registry; a collection of patient information and medical data, over time, about people who have a particular disease or condition, or who receive a particular treatment.

The LLS National Research Registry Protocol will:

1. Answer research questions using data collected from people with blood cancers. Such research involves analyses of subject profile information completed by subjects and medical records data.
2. Obtain permission from LLS National Research Registry research subjects to have Ciitizen, a third-party engaged by LLS, act as their proxy to retrieve full medical record data including images at no cost to research subjects. Note: Patient can choose to upload their medical records into their account, directly.
3. Obtain permission from LLS National Research Registry research subjects to share summary data with research partners (like academic researchers, advocacy groups, and pharmaceutical companies) that are advancing treatments for blood cancer. "Summary data" represents the important elements of medical record data, coded for research use, with personal identifiers like name, address, and phone number removed.
4. Obtain permission from LLS National Research Registry research subjects to be contacted from time to time, for them to provide updated medical information.

Eligibility Criteria:
Inclusion Criteria:

People with blood cancer, before, during, and after blood cancer treatments.

Exclusion Criteria:

People unable or unwilling to sign informed consent.
A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia

You have been asked to participate in this research study because you have or may have oral leukoplakia. Oral leukoplakia is described as a white patch or plaque on the oral mucosa (mouth) that will not rub off and cannot be removed by scraping, reversed by elimination of obvious irritants (things that cause redness and/or swelling) such as dentures (artificial replacment for missing teeth), or lesions as described that are diagnosed by your dentist.

Since oral leukoplakia may precede the development of cancer, using agents that may prevent cancer, called chemoprevention, may be useful. The purpose of this study is to determine whether taking a green tea preparation may have effects on your leukoplakia. It is hoped that these effects may reduce the subsequent risk of cancer in or around the area of leukoplakia. To assess for these effects, samples of the lining of your mouth will be obtained, and they will be analyzed looking for certain features (biomarkers).

Eligibility Criteria:
* Patients with oral leukoplakia without evidence of active infections in the mouth will be invited to participate in this study.
* Patients must currently consume no more than 3 cups of tea a day,
* not be taking large doses of vitamin A or its derivatives (more than 25,000 units), selenium, or beta-carotene.
* Additionally, patients must not participate in this study if they are allergic to caffeine, have GI ulcers, are pregnant, or have had previous invasive mouth cancer.
Feasibility and Effectiveness of a Specialized Brief Intervention for Hazardous Drinkers in an Emergency Department.

Alcohol use and its consequences represent an important public health problem. As well as alcohol dependence, hazardous drinking also contributes to a high burden in terms of morbidity and mortality. To improve these patients' prognosis and decrease associated social and health care costs, it is necessary to increase early detection, intervention and treatment for these problems. For these reasons, SBIRT programmes (Screening Brief Intervention and Referral to Treatment) have been developed, evaluated and shown to be effective, particularly in primary care and general practice. Nevertheless, effectiveness of SBIRT in emergency departments (ED) has not been clearly established.

The investigators aimed to evaluate the feasibility and efficacy of an SBIRT programme in the ED of a tertiary hospital.

The investigators conducted a randomized controlled trial to study the feasibility and efficacy of an SBIRT programme for hazardous drinkers presenting in an ED. All patients older than 18 years old attending the emergency department were potentially eligible. Cognitively impaired or medically unstable patients were excluded. Patients seeking treatment for alcohol use were also excluded. Patients were randomized to two groups, with the control group receiving two leaflets - one regarding alcohol use, and the other giving information about the study protocol. The intervention group received the same leaflets as well as a brief motivational intervention on alcohol use; and, where appropriate, a referral to specialised treatment. The primary outcomes were the proportion of hazardous drinkers measured by AUDIT-C scale and the proportion of patients attending specialised treatment at 1.5 and 4.5 months and 1 year.

Eligibility Criteria:
Inclusion Criteria:

* All patients aged 18 or older attending to the emergency department were potentially eligible patients
* Patients with an AUDIT-C score higher than 6 points for men and 5 for woman were invited to participate

Exclusion Criteria:

* Cognitive impairment
* Medically unstable
* Patients explicitly demanding alcohol treatment
Evaluation of Bone Regeneration After Apical Surgery Using Advanced Platelet-rich Fibrin: Utilization of Ultrasound for the Assessment of Periapical Lesions

The study examines the impact of advanced platelet-rich fibrin (A-PRF) on bone regeneration in apical surgery compared to standard methods. It highlights the effectiveness of ultrasound as a diagnostic tool for assessing periapical lesions. Eligible participants were adults with specific periapical lesions following root canal treatment failures. Exclusions included patients outside specific criteria, like those with advanced periodontal disease or undergoing orthodontic treatment. Participants were randomized into two groups: one receiving A-PRF to enhance bone regeneration and a control group without it. Both groups underwent apical surgery under magnification, with different postoperative protocols. The study involved radiological and ultrasonographic evaluations of lesion size and bone healing at baseline, 6 months, and 12 months, alongside blood analyses for Vitamin D and cholesterol level to assess their potential impact on healing.


Eligibility Criteria:
Inclusion Criteria:

1. Adult patients with precisely defined periapical lesions related to maxillary or mandibular incisors and premolar teeth as a sequel to persistent endodontic infection
2. Patients after root canal treatment/retreatment
3. Patients with or without the sinus tract
4. Patients with root perforations
5. Patients with clinical cases deemed unsuitable for non-surgical endodontic intervention
6. Patients with traumatic lesions clearly indicated for endodontic apical surgery.

Exclusion Criteria:

1. Patients younger than 18 years
2. Patients with lesions unrelated to the root apical area
3. Patients in possession of vital teeth with radiolucency in the apical region
4. Pregnant patients
5. Patients with non-restorable teeth
6. Patients with advanced periodontal disease
7. Patients with uncontrolled systemic health conditions
8. Patients receiving bisphosphonate therapy
9. Patients receiving orthodontic treatment.
Evaluation of Specialized Water Dance Intervention

Individuals with profound intellectual and multiple disabilities (PIMD) have extensive health problems and need for personal assistance throughout the day. Few physical- and health promoting activities are available for them and among the activities, few have been scientifically evaluated. Specialized water dance intervention (SWAN) is a new method developed to relieve discomfort and promote physical wellbeing among people with PIMD. The aim of the study is to evaluate the effects of SWAN on stress, spasticity, pain, alertness, wellbeing and social interaction among individuals with PIMD.

Individuals with profound intellectual and multiple disabilities (PIMD) have extensive health problems and need for personal assistance throughout the day. Few physical and health promoting activities are available for them. Among the activities, few have been scientifically evaluated. Specialized water dance intervention (SWAN) is a new method developed to relieve discomfort and promote physical wellbeing among people with PIMD. The aim of the study is to evaluate the effects of SWAN on stress, spasticity, pain, alertness, wellbeing and social interaction among individuals with PIMD.

Prospective randomized controlled intervention study in which the effects of SWAN are tested in a two-group cross-over design with pre-, under- and post-measurements. The study is conducted as a multicenter study with four participating county councils/regions I Sweden (Varmland County Council, Region Orebro County, Region Ostergotland and Region Gavleborg).

The SWAN intervention is given once a week for 3 months (12 occasions). Each SWAN session is 45 minutes and is led by two SWAN leaders.


Eligibility Criteria:
Inclusion Criteria:

* have a profound intellectual and multiple disabilities corresponding to level IV-V in the Gross Motor Function Classification System.
* aged 16-65 years
* be accustomed to water and not find discomfort of activities in water.

Exclusion Criteria:

* severe hearing impairment/deafness
* have wounds/infections that are infectious in the pool
Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy

Crohn's disease is an inflammatory disorder that can affect any part of the gastrointestinal (GI) tract. Some patients still experience persistent diarrhea or other symptoms such as abdominal pain even when their Crohn's disease is in remission. Diarrhea and/or abdominal pain that is not responsive to standard therapies can significantly affect a patient's quality of life and ability to work. The purpose of this study is to test the safety and effectiveness of the drug ranolazine in reducing Crohn's disease-associated diarrhea and other symptoms. Ranolazine is approved by the US Food \& Drug Administration (FDA) for chronic angina (a heart condition). This study is investigating if ranolazine could be used in the setting of Crohn's disease.


Eligibility Criteria:
Inclusion Criteria:

* Meet diagnostic criteria for Crohn's Disease with active diarrhea Either with active disease or in remission (as defined by endoscopic or radiographic findings) but experiencing symptoms (e.g., diarrhea, abdominal pain)
* Have greater than three loose stools per day

Exclusion Criteria:

* Male and female subjects \<18 years of age
* Significant change in medication including prednisone, antidepressant medications, or stimulants within the last 4 weeks

  a. Allowances include: Rectal hydrocortisone, rectal mesalamine, addition of prednisone (up to 20mg) for flares, etc.
* Regular (daily) use of opioids or other drugs of abuse including heavy alcohol or marijuana use
* Severe psychiatric disease including schizophrenia, psychosis, suicidal depression
* Previous use of ranolazine within 2 months prior to enrollment
* Prior use of ranolazine which was discontinued for safety or tolerability
* Metabolic derangement defined as liver function tests \>3x upper limit of normal or severe renal disease defined as calculated creatinine clearance \<30 mL/min
* Have liver cirrhosis
* Concurrent use of CYP3A inhibitors, inducers, or substrates

  a. These may include: ketoconazole, itraconazole, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir, clarithromycin, or rifampin, rifapentine, phenobarbital, phenytoin, and St. John's Wort, digoxin.
* A family history of (or congenital) long QT syndrome or known acquired QT interval prolongation
* Inability or refusal to give informed consent for any reason including a diagnosis of dementia or cognitive impairment
* Patients who are pregnant or breastfeeding
* Patients who are enrolled in other investigational drug studies or who have taken investigational drugs within 30 days before enrollment
* Other factors which in the opinion of the investigator could potentially impact the study outcomes (e.g., underlying disease, medications, history) or prevent the participant from completing the protocol (poor compliance or unpredictable schedule)
Low Grade Serous Ovarian Carcinoma and Uterine Involvement : Should Hysterectomy be the Rule

Investigators studied a population of 28 low grade serous ovarian carcinoma treated in Hospices civils de Lyon between 2000 and 2022. The primary objective is to determinate the rate of myometrial involvement by the cancer at pathology examination. Then, investigators compared patients with or without myometrial involvement : survival parameters, predictive factors of myometrial involvement (age, CA 125 level, surgery characteristics, pathology characteristics).


Eligibility Criteria:
* Inclusion Criteria :

  * 18 years old or more
  * low grade serous ovarian cancer (MDACC classification)
  * Grade 1 serous ovarian carcinoma (Silverberg classification)
* Exclusion Criteria :

  * no sufficient data available
  * grade 2 and 3 serous ovarian carcinoma
Identification and Treatment of Diabetes In Solid Organ Transplant Recipients

The purpose of this study is to determine the influence of post-transplant diabetes on medical and psychosocial outcomes in individuals who receive solid-organ transplant prior to 18 years of age and their families.

This study seeks to understand how organ transplant patients are affected by the development of diabetes, and to test whether early diagnosis of diabetes and comprehensive professional support will:

1. facilitate the adjustment of children and their families to the rigors of diabetes care
2. improve adherence to medication regimens
3. reduce acute complications of diabetes and organ rejection.

Eligibility Criteria:
Inclusion Criteria:

* Patients of Children's Healthcare of Atlanta who have received a kidney, liver, or heart transplant

Exclusion Criteria:

* Received a transplant after 18 years of age
* Cognitively unable to participant as determined by the study team psychologist
* Not receiving a solid organ transplant for kidney, liver, or heart
* Declines participation invitation
Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer

With the recent approval of Nivolumab for second-line treatment of stage IIIb/IV non-small cell lung cancer (NSCLC), immune checkpoint inhibitors are entering the standard of care for lung cancer. Other immune checkpoint inhibitors are under evaluation, both in resectable and non-resectable NSCLC. In order to refine our use of these molecules, comprehensive data on the immune contexture of NSCLC are needed. Moreover,a blood marker of this contexture would allow physicians to monitor the immune status of their patient's tumor and though to evaluate the rightful place of immunotherapy in the multimodal treatment of NSCLC. No such blood marker has been validated so far. The LYMPHOLUNG study investigate the concordance between blood and intratumoral counts of immune cells in resectable stage I to IIIA NSCLC. By the use of 30-marker cytometry, a precise immune profile of NSCLC will be depicted. The prognostic value of the circulating and intra-tumoral T regulator over total lymphocytes ratio for 2-year recurrence-free survival will also be addressed.


Eligibility Criteria:
Inclusion Criteria:

* Men and women over 18 years of age
* Histologically- or cytologically- confirmed non-small cell lung cancer diagnostic
* Stage I, II or IIIA NSCLC (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology). Staging must have included an abdominal and thoracic CTscan, a CTscan or MRI of the brain and a 18FDG PETscan
* Subjects for whom a surgical resection is indicated
* Signed written informed consent

Exclusion Criteria:

* - previous, ongoing or planned neo-adjuvant treatment (chemotherapy, targeted therapy, immunotherapy or radiotherapy)
* contraindications to general anesthesia
* contraindication to the planned surgical resection
* history of immunosuppressive disorder
* known history of testing positive for human immunodeficiency virus
* subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 30 days of randomization.
* clinical suspicion of active infection (either acute or chronic)
* severe (hemoglobin \< 8.0 g/dL) or symptomatic anemia
* women of childbearing potential must have a negative urine pregnancy test
* women must not be breastfeeding
* prisoners or subjects who are involuntarily incarcerated
* subjects under guardianship
Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

This trial is a multi-center, open, single-dose, dose-increasing trial，to evaluate the safety and efficacy of STSG-0002 injection in patients with chronic hepatitis B treated with oral antiviral therapy(Long-term follow-up).


Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic HBV；
* Receiving anti-HB viral therapy；
* 10 IU/ml≤HBsAg≤3000 IU/ml.

Exclusion Criteria:

* Patients co-infected with hepatitis C virus, HIV, HAV, HDV, HEV;
* Liver cirrhosis;
* Hepatocellular carcinoma;
* Autoimmune liver disease;
* Clinical hepatic decompensation;
* Fibroscan\>12 kPa;
* a. hemoglobin\<110g/L（female）\<120 g/L（male），platelet\<ULN，white blood cell\<2.5×109/L；b. bilirubin\>1.5 ×ULN，ALT\>2 × ULN，serum albumin\<35 g/L；c. INR\>1.5；d. serum creatinine \>1.5×ULN.
A Comparison of ESP Block to SSN Block for Analgesia in Shoulder Surgery

A comparison between Erector Spinae Plane block and Suprascapular nerve block in providing analgesia for shoulder surgery

Suprascapular nerve block is considered a phrenic nerve sparing approach that recently introduced as alternative for interscalene brachial plexus nerve block in shoulder surgery. However, some researchers reported that Suprascapular nerve block alone results in an ineffective analgesia. Erector Spinae Plane block is supposed to be able in providing adequate analgesia in shoulder surgery

Eligibility Criteria:
Inclusion Criteria:

* ASA I and II,
* Age above 21 years and below 60 years in both sexes,
* Cooperative patients,
* Patients with a BMI (body mass index) not exceeding 35.

Exclusion Criteria:

* patients with cardiovascular or respiratory compromise,
* Patient refusal,
* Coagulopathy,
* Local tissue infection,
* Allergy to local anesthesia,
* prior to cervical or thoracic spine surgery.
Continuous Popliteal Nerve Blocks: Effect of Perineural Catheter Tip Location Relative to the Sciatic Nerve Bifurcation on Postoperative Analgesia

Research study to determine the relationship between perineural catheter tip location relative to the sciatic nerve bifurcation and postoperative analgesia for continuous popliteal nerve blocks.

Hypothesis: During a continuous popliteal nerve block, postoperative analgesia will be improved with the perineural catheter tip at the level of the sciatic nerve bifurcation compared to when the catheter tip is 5 cm cephalad/proximal to the bifurcation.

Eligibility Criteria:
Inclusion Criteria:

* undergoing surgery with a popliteal perineural catheter for postoperative analgesia
* age 18 years or older

Exclusion Criteria:

* pregnancy
* inability to communicate with the investigators and hospital staff
* incarceration
* clinical neuropathy in the surgical extremity
* chronic high-dose opioid use
* a history of opioid abuse
* surgery outside of ipsilateral sciatic and saphenous nerve distributions
Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)

An open label, prospective, randomized cross-over phase II study in up to 60 sickle cell patients who are either homozygous for Hb S or have HbSB0 thalassemia. Initially, each patient will be treated for 6 weeks with placebo or a standard dose of propranolol (40 mg) every 12 hrs. This will be followed by a 2-week washout period after which, patients will receive the other treatment modality (placebo or propranolol).

We Hypothesize that propranolol administered in vivo on a daily basis for 6 weeks (1) will decrease baseline adhesion to endothelial cells and will substantially abrogate epinephrine-stimulated adhesion to endothelial cells, as measured in vitro; (2) will improve biomarkers of endothelial activation and dysfunction; and (3) can be safely used in patients with SCD. Thus, the use of propranolol in SCD may represent a safe and effective means of anti-adhesive therapy in SCD.

Study Objectives:

Primary Objective:

• To establish the safety and efficacy of long-term therapy with propranolol as an anti-adhesive therapy for SCD.

Secondary Objective:

• To evaluate changes in soluble markers of endothelial activation and dysfunction.

Correlative Science Objective:

• To determine whether response to propranolol therapy is associated with polymorphisms in genes encoding the proteins involved in the upregulation of Sickle Red Blood Cell (SS RBC) adhesion by epinephrine.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis by electrophoresis (HEP) of Hemoglobin (Hgb) SS or Hgb Sβ0 thalassemia (all patients followed at our clinic have HEP-confirmed diagnosis on file)
* Age ≥ 18 years
* Blood pressure (BP) Systolic ≥ 95mm Hg and Diastolic ≥ 50mm Hg
* Heart rate (HR) ≥ 70 and ≤ 110 bpm
* Oxygen saturation by pulse oximeter and at room air ≥ 92%
* Hematocrit (Hct) ≥ 20% and Hb \> 6.0 g/dL
* Euthyroid status as indicated by normal Thyroid Stimulating Hormone (TSH)
* SS RBCs obtained during screening period demonstrating an adhesion response to epinephrine of 40% over non-stimulated baseline adhesion to endothelial cells
* Capacity to understand and sign informed consent

Exclusion Criteria:

* History of vaso-occlusive episode during the 6 wks prior to screening
* RBC transfusion during the 3 months prior to study entry
* Ongoing pregnancy
* History of heart failure, myocardial infarct (MI), bradyarrhythmias, conduction defects
* History of asthma or reactive airway disease
* History of thyroid disease
* Diabetes
* Renal insufficiency (BUN \>21 mg/dL and/or Creatinine \>1.4 mg/dL)
* Use during the screening or study period of any of the following medications: antihypertensives, diuretics, thyroid replacement therapy, anti-arrhythmia medications, bronchodilators, inhaled steroids, insulin, or hypoglycemic medication
* History of allergy to sulfonamides